ANCILLARY STUDY TO THE HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRR

针对 CIRR 的丙型肝炎抗病毒长期治疗的辅助研究

• 批准号: 7982147
• 负责人: KAREN L LINDSAY
• 金额: $ 1.51万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7982147
• 关键词: Ancillary Study; Ascites; Carcinoma; Cessation of life; Chronic; Clinical; Clinical Research; Combined Modality Therapy; Computer Retrieval of Information on Scientific Projects Database; Fibrosis; Frequencies; Funding; Grant; Hemorrhage; Hepatitis C Antiviral; Institution; Outcome; Patients; Research; Research Personnel; Resources; Source; Staging; United States National Institutes of Health; cohort; experience; liver transplantation; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To establish a cohort of chronic hepatitits C patients with Ishak stage 3-6 fibrosis who experienced a sustained virologic response (SVR) after peginterferon and ribavarin combination therapy and assess the frequency of clinical outcomces (variceal bleeding, ascites, CTP scores> 7, liver transplants, death) and heptocellular carcinoma (HCC) and factors associated with these outcomes.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 建立一组Ishak 3-6期纤维化的慢性丙型肝炎患者，这些患者在聚乙二醇干扰素和利巴韦林联合治疗后出现持续病毒学应答（SVR），并评估临床结局（静脉曲张出血、腹水、CTP评分> 7、肝移植、死亡）和肝细胞癌（HCC）的频率以及与这些结局相关的因素。